Mifepristone 300 MG [Korlym] + Placebo for mifepristone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypercortisolism
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Trial Timeline
Mar 31, 2023 → Dec 18, 2024
NCT ID
NCT05772169About Mifepristone 300 MG [Korlym] + Placebo for mifepristone
Mifepristone 300 MG [Korlym] + Placebo for mifepristone is a approved stage product being developed by Corcept Therapeutics for Hypercortisolism. The current trial status is completed. This product is registered under clinical trial identifier NCT05772169. Target conditions include Hypercortisolism, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05772169 | Approved | Completed |
Competing Products
1 competing product in Hypercortisolism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Relacorilant | Corcept Therapeutics | Phase 3 | 72 |